Are Short-Stay Units Safe and Effective in the Treatment of Non-Variceal Upper Gastrointestinal Bleeding?

Introduction: emergency department (ED) overcrowding is a health, political, and economic problem of concern worldwide. the causes of overcrowding are an aging population, an increase in chronic diseases, a lack of access to primary care, and a lack of resources in communities. overcrowding has been associated with an increased risk of mortality. the establishment of a short stay Unit (SSU) for conditions that cannot be treated at home but require treatment and hospitalization for up to 72 h may be a solution. SSU can significantly reduce hospital length of stay (LOS) for certain conditions but does not appear to be useful for other diseases. currently, there are no studies addressing the efficacy of SSU in the treatment of non-variceal upper gastrointestinal bleeding (NVUGIB). our study aims to evaluate the efficacy of SSU in reducing the need for hospitalization, LOS, hospital readmission, and mortality in patients with NVUGIB compared with admission to the regular ward. materials and methods: this was a retrospective, single-center observational study. medical records of patients presenting with NVUGIB to ED between 1 april 2021, and 30 september 2022, were analyzed. we included patients aged >18 years who presented to ED with acute upper gastrointestinal tract blood loss. the test population was divided into two groups: patients admitted to a normal inpatient ward (control) and patients treated at SSU (intervention). clinical and medical history data were collected for both groups. the hospital LOS was the primary outcome. secondary outcomes were time to endoscopy, number of blood units transfused, readmission to the hospital at 30 days, and in-hospital mortality. results: the analysis included 120 patients with a mean age of 70 years, 54% of whom were men. sixty patients were admitted to SSU. patients admitted to the medical ward had a higher mean age. the glasgow-blatchford score, used to assess bleeding risk, mortality, and hospital readmission were similar in the study groups. multivariate analysis after adjustment for confounders found that the only factor independently associated with shorter LOS was admission to SSU (p < 0.0001). admission to SSU was also independently and significantly associated with a shorter time to endoscopy (p < 0.001). the only other factor associated with a shorter time to EGDS was creatinine level (p = 0.05), while home treatment with PPI was associated with a longer time to endoscopy. LOS, time to endoscopy, number of patients requiring transfusion, and number of units of blood transfused were significantly lower in patients admitted to SSU than in the control group. conclusions: the results of the study show that treatment of NVUGIB in SSU can significantly reduce the time required for endoscopy, the hospital LOS, and the number of transfused blood units without increasing mortality and hospital readmission. treatment of NVUGIB at SSU may therefore help to reduce ED overcrowding but multicenter randomized controlled trials are needed to confirm these data